Copyright © 1999 by the European Society of Cardiology.
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry
a Duke University, Durham, U.S.A.
b II.Med. Universitätsklinik Mannheim/Heidelberg, Heidelberg, Germany
c Astra Hassle, Goteborg, Sweden
d Warsaw University School of Medicine, Warsaw, Poland
e GISSI group, Milano, Italy
f University of Glasgow, Glasgow, U.K.
g Astra Pharmaceuticals LP, Wayne, U.S.A.
h Montreal Heart Institute, Montreal, Canada
i Brigham & Women's Hospital, Boston, U.S.A.
j Goteborg University, Goteborg, Sweden
k Cleveland Clinic, Cleveland, U.S.A.
l McMaster University, Hamilton, Canada
revised December 15, 1998; accepted December 16, 1999 1999
Abstract
Aims The reported prevalence of angiotensin-converting enzyme (ACE) inhibitor use in patients with heart failure varies considerably. Recent reports suggest that many patients who could benefit from such therapy are not receiving ACE inhibitors. The Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry was established to understand better the demographics, characteristics, and contemporary use of ACE inhibitors in an international registry.
Methods and Results Between August 1996 and April 1997, each of 105 study centres from eight countries in North America and Europe was invited to review retrospectively the medical records of 100 consecutive patients with left ventricular ejection fractions 
35%. The median age of the 9580 Registry patients was 66 years, 26% were women, the median ejection fraction was 27%, and the primary aetiology of left ventricular dysfunction was ischaemic (63%). Eighty percent of patients were receiving ACE inhibitors. The most common reason for non-use of ACE inhibitors was intolerance (9%).
Conclusion The SPICE Registry provides a contemporary description of the demographics and management of patients with documented left ventricular systolic dysfunction. The contemporary use of ACE inhibitors (80%) appears to be higher than previously reported and the main reason for non-use is perceived intolerance (9%).
Key Words: Heart failure, ACE inhibitor, management, medication usage
f1 Correspondence: Bradley A. Bart, MD, Assistant Professor of Medicine, Division of Cardiology, Hennepin County Medical Center, 865A, 701 Park Avenue South, Minneapolis, Minnesota 55415, U.S.A.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. F Potthoff, G. E Tudor, K. S Pieper, and V. Hasselblad Can one assess whether missing data are missing at random in medical studies? Statistical Methods in Medical Research, June 1, 2006; 15(3): 213 - 234. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Westendorp, R. G. Schoemaker, H. Buikema, F. Boomsma, D. J. van Veldhuisen, and W. H. van Gilst Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction Eur J Heart Fail, March 1, 2006; 8(2): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.V. McMurray The role of angiotensin II receptor blockers in the management of heart failure Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J10 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ertl and S. Frantz Wound model of myocardial infarction Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H981 - H983. [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Young, M. E. Dunlap, M. A. Pfeffer, J. L. Probstfield, A. Cohen-Solal, R. Dietz, C. B. Granger, J. Hradec, J. Kuch, R. S. McKelvie, et al. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low-Left Ventricular Ejection Fraction Trials Circulation, October 26, 2004; 110(17): 2618 - 2626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kittleson, S. Hurwitz, M. R. Shah, A. Nohria, E. Lewis, M. Givertz, J. Fang, J. Jarcho, G. Mudge, and L. W. Stevenson Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2029 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Weber Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes? Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C1 - C4. [Abstract] [PDF]
|
|
|
|
|
|
J.N. Cohn Val-HeFT: changing the heart failure horizon Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C25 - C28. [Abstract] [PDF]
|
|
|
|
 |
|
 A P Maggioni, G Sinagra, C Opasich, E Geraci, M Gorini, E Gronda, D Lucci, G Tognoni, E Balli, and L Tavazzi Treatment of chronic heart failure with {beta} adrenergic blockade beyond controlled clinical trials: the BRING-UP experience Heart, March 1, 2003; 89(3): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Maggioni, I. Anand, S. O. Gottlieb, R. Latini, G. Tognoni, J. N. Cohn, and the Val-HeFT Investigators Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1414 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Greenberg Angiotensin receptor blockers in heart failure: A work in progress J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1422 - 1424. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fink The Use of Angiotensin-II Receptor Blockers in Heart Failure Journal of Pharmacy Practice, August 1, 2002; 15(4): 318 - 325. [Abstract] [PDF]
|
|
|
|
|
|
P. Jong, C. Demers, R. S. McKelvie, and P. P. Liu Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials J. Am. Coll. Cardiol., February 6, 2002; 39(3): 463 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Skali and M. A Pfeffer Review: Prospects for ARB in the next five years Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 215 - 218. [PDF]
|
|
|
|
 |
|
 D. J. Whellan, L. Gaulden, W. A. Gattis, B. Granger, S. D. Russell, M. A. Blazing, M. S. Cuffe, and C. M. O'Connor The Benefit of Implementing a Heart Failure Disease Management Program Arch Intern Med, October 8, 2001; 161(18): 2223 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bellotti, L.P. Badano, N. Acquarone, R. Griffo, G. Lo Pinto, A.P. Maggioni, C. Mattiauda, G. Menardo, and P. Mombelloni Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR study Eur. Heart J., April 1, 2001; 22(7): 596 - 604. [Abstract] [PDF]
|
|
|
|
|
|
A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure Arch Intern Med, March 12, 2001; 161(5): 667 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stewart, L. Blue, S. Capewell, J. D. Horowitz, and J. J. McMurray Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure Eur J Heart Fail, March 1, 2001; 3(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Clark Perioperative Treatment of Congestive Heart Failure Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2000; 4(4): 223 - 235. [Abstract] [PDF]
|
|
|
|
|
|
J. J McMurray and S. Stewart HEART FAILURE: Epidemiology, aetiology, and prognosis of heart failure Heart, May 1, 2000; 83(5): 596 - 602. [Full Text]
|
|
|
|
 |
|
 R. M. Califf and C. M. O'Connor {beta}-Blocker Therapy for Heart Failure: The Evidence Is In, Now the Work Begins JAMA, March 8, 2000; 283(10): 1335 - 1337. [Full Text] [PDF]
|
|
|
|
|
|
K. Dickstein ACE inhibitor use in heart failure: would that it were so Eur. Heart J., August 2, 1999; 20(16): 1145 - 1146. [PDF]
|
|
|
|
 |
|
 S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF]
|
|